Please login to the form below

Not currently logged in
Email:
Password:

Nycomed markets Bonviva drug in Asia

Nycomed has become marketing authorisation holder of osteoporosis treatment Bonviva in key Asia-Pacific countries

Nycomed has completed the transfer of marketing authorisation approval for osteoporosis treatment Bonviva (Ibandronate) in a number of key Asia Pacific markets.

The licensing and supply agreement with Roche covers China, Hong Kong, Malaysia, Australia, New Zealand, Philippines, Singapore, Taiwan and Vietnam, with a future option to commercialise Bonviva in additional Asia Pacific territories.

Under the terms of the deal, Nycomed will hold marketing authorisation holder in all the licensed territories. Bonviva is a bisphosphonate used in the treatment of osteoporosis in post-menopausal women.

Financial details of the agreement were not disclosed.

Guido Oelkers, executive vice-president of commercial operations, said: "The in-licensing of Bonviva from Roche is another important step towards Nycomed's expansion in the Asia Pacific region and demonstrates our growing attraction as a marketing partner for leading companies and brands in these dynamic countries.”

Nycomed recently opened offices in China, South Korea, Indonesia, Malaysia and the Philippines.

15th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...